Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Millions and millions of buys...
Yet this thing still sits at 51. What gives?
Ooops wrong board :)
PINCH!!!!
News!
Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTA 01/07 01:02 PM
DALLAS, Jan. 7 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.BeaconEquity.com/m
Today's Trade Alerts include: Walter Industries Inc. (WLT:$23.67,00$-2.03,00-7.90%) , Smurfit-Stone Container Corp. (SSCC:$0.437,0$0.007,01.63%) , Finisar Corp. (FNSR:$0.5102,$-0.0498,-8.89%) , Charter Communications Inc. (CHTR:$0.162,0$0.0598,58.51%) , Star Scientific Inc. (STSI:$3.59,00$-0.11,00-2.97%) and Genta Inc. (GNTA:$0.0055,$-0.0015,-21.43%) .
Join the fastest growing investment community at: http://www.stockhideout.com
See what Cramer has to say about these stocks at: http://maddmoney.net/
BeaconEquity.com's Trade Alerts are brief analyses on the active stocks each day that are affecting the markets. These include breaking news, insider activity, recent 52-week highs/lows, technical breakouts, and other market driving information. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry's largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com/m CRD# 1755680
BeaconEquity.com Disclosure
BeaconEquity.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BeaconEquity.com is a wholly owned entity of BlueWave Advisors, LLC, a financial public relations firm. Please read our report and visit our website, BeaconEquity.com, for complete risks and disclosures.
Beacon Equity ResearchJeff Bishop, (469)-252-3505
press@beaconequity.com
Reuben Sushman of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 1755680.
SOURCE BeaconEquity.com
It's not magical. Where did I say it was magical?
Lots of buying now!
Come on baby, bust through that 55
Uhhh....Huge. Worldwide Leukemia sufferers immediately, more applications in the future.
Upside for Genta is astounding.
Yeah, finally got filled but it took a while.
I can't get filled!
I should've gotten in at 49 when I had the chance...
@#T^@#
Time to roll, great price here.
I ain't goin nooo where, no where baaabaaaay
Can someone please explain NITE to me?
Closed at .007, I'll take it baby!
Wait...
...I thought it was just down?
Followed by a 5MM share buy
Nothing bad is happening here, what are you talking about. Watch this close.
We began yesterday's run at .0061 @3:15pm
We'll start todays at or around .007
Better get in now folks! Beat the rush!
We're well above where we were yesterday when we made the run. Gonna be fun!!
Genta is regulated by the FDA and info can be found about them on the FDA website. This is a reporting company on the BB and not a stinky pinky.
http://www.fda.gov/ohrms/dockets/usi...ies2007/sg.htm
We goin' sizzlin' we goin' sizzzlin'!
Panic for no real good reason. The stock is so undervalued at this point it's ABSURD not to get in. Don't be someone who misses the ride.
Here we go boys and gals!
This is exactly what needs to happen.
The candles needed to come back inside the bollinger bands before the next leg up...that's exactly what's happening right now and it's a beautiful thing. This is a classic chart. Beautiful.
PUSH HOD!! Better get in now folks!
One more tic for the HOD!!
Holy shnikees.
People need to get in today, tomorrow might be a little late to the party!
It's hard to believe how much this stock....
Jumped with the release of the orphan drug FDA approval. Can you picture what this things gonna do when Genasense gets approval.
Good lord, where will I park my yacht after I learn how to drive it?
Off and runnin!!
Still waaaaaaaaaaaay undervalued here. Absolutely no reason for the drop off on the 8th of Dec.
There really is no telling. Tremendous upside with GNTA right now and it's been beaten down to a pulp by panic filled investors. Not fair at all.
This is one of the most undervalued stocks on the board right now.
Incredible upside.
cardsfan, I'd say at least back to the pre-DEC 8th levels. You gotta believe that it would likely double that.
Geez, imagine the pop if this is followed up in a few days/weeks with FDA Genasense approval. Hoooooly cow.
Anyone see the GNTA news this morning?
GNTA has much more in the pipeline than Genasense. Panic was the reason for the sell-off back in December. Then Genta released a statement that they wanted to review an amended NDA with the senior leadership from the FDA. At .0037, how can anyone afford NOT to throw a few hundred dollars at this? Talk about undervalued.
You are annoying.
News!!
Genta Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane in Clinical Development 01/05 08:21 AM
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (GNTA:$0.0037,$0.0010,37.04%) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug†for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
In the completed Phase 2 study, 35 patients with advanced gastric cancer were treated with tesetaxel at doses ranging from 27 to 35 mg/m2 once every three weeks. All patients had received extensive prior treatment, having failed a combination regimen that included cisplatin plus 5-fluorouracil or Xeloda®, and all but 2 patients had received a third chemotherapy drug with this regimen. Final intent-to-treat analysis, including all patients enrolled in the study, showed that 5 patients achieved a partial response, 2 patients achieved a partial response unconfirmed by CT scan, and 14 patients achieved stable disease, for an overall major response rate of 20% and a disease-control rate of 60%. The most serious adverse reaction was Grade 3-4 neutropenia, which occurred in 57% of patients. Six patients failed to complete the first course of treatment. Five patients died on study from differing causes that included intestinal perforation, pneumonia, hepatic failure, hemorrhagic shock, and rapid disease progression. One patient withdrew before receiving the first treatment dose.
“These response data for tesetaxel in a critically ill patient population show clinical activity at levels that are at least comparable to studies with other taxanes,†said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Based on these data, we have consulted extensively with international experts and will be defining a global registration path for tesetaxel as a 2nd-line treatment for patients with advanced gastric cancer. FDA designation as an Orphan Drug provides important assistance in the clinical development process.â€
About Tesetaxel
Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.
About Genta (GNTA:$0.0037,$0.0010,37.04%)
Genta Incorporated (GNTA:$0.0037,$0.0010,37.04%) is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta (GNTA:$0.0037,$0.0010,37.04%) is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient†basis in countries outside the United States. For more information about Genta (GNTA:$0.0037,$0.0010,37.04%) , please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated (GNTA:$0.0037,$0.0010,37.04%) . By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact.The words “potentiallyâ€, “anticipateâ€, “couldâ€, “calls forâ€, and similar expressions also identify forward-looking statements.The Company does not undertake to update any forward-looking statements.Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration (“FDAâ€);
the safety and efficacy of the Company’s products or product candidates;
the Company’s assessment of its clinical trials;
the commencement and completion of clinical trials;
the Company’s ability to develop, manufacture, license and sell its products or product candidates;
the Company’s ability to enter into and successfully execute license and collaborative agreements, if any;
the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially.For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.
Source: Genta Incorporated (GNTA:$0.0037,$0.0010,37.04%)
Hey you guys!
Brand new to the University. I'm so excited by what I'm reading out of the more tenured participants. I'm really new to investing from an overall perspective, so I'm looking to learn the basics!
Thanks, Chartinator!